Posted by Michael Wonder on 16 Apr 2025
FDA grants fast track status to Prescient’s PTX-100, advancing commercialisation pathway
16 April 2025 - Prescient Therapeutics has received fast track designation from the US FDA for its lead candidate PTX-100, putting the company closer to potential accelerated approval – a central component of its commercialisation strategy.
The designation, which applies to the treatment of adults with relapsed or refractory mycosis fungoides – the most common subtype of cutaneous T cell lymphoma – offers Prescient several regulatory advantages.
